IL293613A - Combination immunotherapy of il-15 and cd40 agonist in cancer treatment - Google Patents

Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Info

Publication number
IL293613A
IL293613A IL293613A IL29361322A IL293613A IL 293613 A IL293613 A IL 293613A IL 293613 A IL293613 A IL 293613A IL 29361322 A IL29361322 A IL 29361322A IL 293613 A IL293613 A IL 293613A
Authority
IL
Israel
Prior art keywords
tumour
cells
dose
agonist
combination
Prior art date
Application number
IL293613A
Other languages
English (en)
Hebrew (he)
Inventor
Evelien Smits
Jonas Vanaudenaerde
Marc Peeters
Original Assignee
Univ Antwerpen
Univ Ziekenhuis Antwerpen
Evelien Smits
Jonas Vanaudenaerde
Marc Peeters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Antwerpen, Univ Ziekenhuis Antwerpen, Evelien Smits, Jonas Vanaudenaerde, Marc Peeters filed Critical Univ Antwerpen
Publication of IL293613A publication Critical patent/IL293613A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL293613A 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment IL293613A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214049 2019-12-06
PCT/EP2020/084665 WO2021110930A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Publications (1)

Publication Number Publication Date
IL293613A true IL293613A (en) 2022-08-01

Family

ID=68808124

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293613A IL293613A (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Country Status (8)

Country Link
US (1) US20220411524A1 (https=)
EP (1) EP4069739A1 (https=)
JP (1) JP2023505303A (https=)
CN (1) CN115052891A (https=)
AU (1) AU2020395907A1 (https=)
CA (1) CA3163777A1 (https=)
IL (1) IL293613A (https=)
WO (1) WO2021110930A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523181A (ja) * 2021-06-03 2024-06-28 アペクシジェン アメリカ， インコーポレイテッド Ｃｄ－４０アゴニストを用いてがんを処置する方法
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20220411524A1 (en) 2022-12-29
JP2023505303A (ja) 2023-02-08
WO2021110930A1 (en) 2021-06-10
EP4069739A1 (en) 2022-10-12
CA3163777A1 (en) 2021-06-10
AU2020395907A1 (en) 2022-07-21
CN115052891A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
US11730803B2 (en) Cancer immunotherapy using virus particles
Jarosz-Biej et al. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
JP6416926B2 (ja) ガン標的化ｉｌ−１２免疫療法
BR112021000353A2 (pt) inibidores de tgfb1 de alta afinidade, isoforma-seletivos, e seus usos
CN111936164A (zh) 癌的治疗和/或预防用药物组合物
PT2752189T (pt) Utilização de anticorpos anti-fcev em combinação com quimioterpia para o tratamento de cancro da mama
US20230227549A1 (en) Oncolytic virus compositions and methods for the treatment of cancer
US20220411524A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
CA3167386A1 (en) A bacterial composition for the treatment of cancer
KR20190051983A (ko) 암의 치료를 위한 abx196을 포함하는 조합물
US20230270861A1 (en) Inhibitors of the Artemin Pathway for Treatment of Cancer
EP3297668B1 (en) Combination of anti-fgfr4-antibody and bile acid sequestrant
CN119326902A (zh) 癌症联合治疗的组合物与方法
US20240009275A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
Gong et al. Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy
CN114225023B (zh) 抗csf-1r抗体联合抗pd-l1抗体的应用
WO2019133245A1 (en) Preventing cytokine release syndrome
US20240010740A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
EP4681707A1 (en) Method for treating diseases by using reparixin alone or in combination with anti-pd-1 antibody